Gefitinib is approved by the Food and Drug Administration (FDA) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not gotten better after treatment with other chemotherapy. It is available only as part of a special program called the Iressa Access Program. Gefitinib is also being studied in the treatment of other types of cancer.
Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.
A new study describes two promising small molecules that inhibit a host cell factor, called nucleotide binding oligomerization domain-containing protein 2 (NOD2), that inhibits the replication and spread of many arboviruses. This could lead to the development of broad-spectrum antivirals. The study's findings have been published on the preprint server bioRxiv*.
Professor Mark Cragg speaks to News-Medical about his research which involves turning autoimmunity drugs into anti-cancer treatments.
Artificial intelligence deep learning algorithms may predict response to systemic treatment for non-small cell lung cancer.
Using standard-of-care computed tomography scans in patients with advanced non-small cell lung cancer, researchers utilized artificial intelligence to train algorithms to predict tumor sensitivity to three systemic cancer therapies.
Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor activating mutations.
An increase in the incidence and mortality rate of cancer has been noted worldwide, especially for lung cancer.
A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought.
Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer(NSCLC), shows a randomized study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
Hokkaido University researchers have uncovered a cellular protein that stabilizes a tumor promoting signaling pathway, suggesting a new target to treat prostate cancer.
Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, sumultaneously published in The New England Journal of Medicine.
Researchers investigating ways to deliver high doses of cancer-killing drugs inside tumors have shown they can use a laser and light-activated gold nanoparticles to remotely trigger the release of approved cancer drugs inside cancer cells in laboratory cultures.
Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC).
The targeted therapy gefitinib appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy.
Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option. Potential NSCLC patients usually undergo invasive tissue biopsy, which may often be unnecessary and delays treatment.
Treating the brain with a preventative course of radiation may help Small Cell Lung Cancer (SCLC) patients - whose tumors often spread to their brain -- live longer, according to a new study from researchers in the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania.
Researchers at the University of Bradford have discovered a way to prevent chemotherapy resistance in lung cancer by blocking a protein found in cancer cells.
Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy.
As scientists learn more about which genetic mutations are driving different types of cancer, they're targeting treatments to small numbers of patients with the potential for big payoffs in improved outcomes.
Researchers report in the journal Cancer Cell an experimental therapy that in laboratory tests on human cells and mouse models stops aggressive, treatment-resistant and deadly brain cancers called glioblastoma and high-grade gliomas.